HitGen and BioAge Identify Alzheimer's, Cardiovascular Candidates
publication date: Apr 6, 2021
HitGen of Chengdu has identified novel small-molecule compounds for a high-value biological target in a collaboration with BioAge Labs, a San Francisco area biopharma. Dysregulation of the target, a critical component of the innate immune system, is linked to the underlying cause of severe diseases in elderly humans, such as Alzheimer's and cardiovascular disease, according to the companies. To identify the compounds, HitGen screened its DNA encoded library (DEL), which now contains over 1 trillion small molecules. More details....
Stock Symbol: (SHA: 688222)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.